CBSC (Cardiac Biotech Solutions) Debt-to-Asset : 2.07 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cardiac Biotech Solutions Debt-to-Asset?

Cardiac Biotech Solutions CBSC Debt-to-Asset is 2.07 as of Jun. 2025.

Cardiac Biotech Solutions's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was $0.36 Mil. Cardiac Biotech Solutions's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was $0.00 Mil. Cardiac Biotech Solutions's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2025 was $0.17 Mil. Cardiac Biotech Solutions's debt to asset for the quarter that ended in Jun. 2025 was 2.07.

Cardiac Biotech Solutions  (OTCPK:CBSC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Cardiac Biotech Solutions Debt-to-Asset Related Terms

Cardiac Biotech Solutions Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Cardiac Biotech Solutions's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiac Biotech Solutions Debt-to-Asset Chart

Cardiac Biotech Solutions Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Debt-to-Asset
1.25 0.07 0.33 0.07 1.58

Cardiac Biotech Solutions Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.14 0.52 1.58 2.07

CBSC vs LUCY, NXGL, MHUAF: Debt-to-Asset Comparison

For the Medical Instruments & Supplies subindustry, Cardiac Biotech Solutions's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiac Biotech Solutions Debt-to-Asset vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cardiac Biotech Solutions's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cardiac Biotech Solutions's Debt-to-Asset falls into.


Cardiac Biotech Solutions Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cardiac Biotech Solutions's Debt-to-Asset for the fiscal year that ended in Mar. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.263 + 0) / 0.167
=1.57

Cardiac Biotech Solutions's Debt-to-Asset for the quarter that ended in Jun. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.358 + 0) / 0.173
=2.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 2.07 mean?
Cardiac Biotech Solutions (CBSC) has a Debt-to-Asset of 2.07 as of Jun. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Cardiac Biotech Solutions and its competitors.
Is Cardiac Biotech Solutions' Debt-to-Asset too high?
Cardiac Biotech Solutions' current Debt-to-Asset is 2.07.
How does Cardiac Biotech Solutions' Debt-to-Asset compare to LUCY and NXGL?
Cardiac Biotech Solutions' Debt-to-Asset of 2.07 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Medical Devices & Instruments company?
A good Debt-to-Asset depends on the Medical Devices & Instruments industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Cardiac Biotech Solutions and its competitors. Cardiac Biotech Solutions's current Debt-to-Asset is 2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiac Biotech Solutions stock overvalued right now?
Cardiac Biotech Solutions (CBSC) has a current Debt-to-Asset of 2.07. The current Debt-to-Asset is 2.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current Debt-to-Asset is 2.07 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiac Biotech Solutions Business Description

Address 10845 Griffith Peak Drive, Suite 200, Las Vegas, NV, USA, 89135
Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.